Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
about
Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary MyelofibrosisPolycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and managementGenetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progressionVenous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-α therapy.Ruxolitinib: a new treatment option for myelofibrosis.Immunogenicity and other problems associated with the use of biopharmaceuticals.Ruxolitinib versus standard therapy for the treatment of polycythemia vera.Safety considerations when treating myelofibrosis.Safety, Tolerability, and Immunogenicity of InterferonsAnnual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Pharmacological management of essential thrombocythemia.Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cellsChronic myeloproliferative neoplasms: a collaborative approach.Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.How I treat essential thrombocythemia.Current and future treatment options for polycythemia vera.The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cellsJAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapyPegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia veraPhase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosisPhiladelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.Deactylase inhibition in myeloproliferative neoplasms.Interferon-α in acute myeloid leukemia: an old drug revisited.Therapeutic approaches in myelofibrosis.Rational therapeutic options for patients with myeloproliferative neoplasms.A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Interferon α may be back on track to treat acute myeloid leukemia.Emerging drugs for polycythemia vera.Genetic basis of MPN: Beyond JAK2-V617F.Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
P2860
Q26774212-F0FC3E86-F4A0-4ECA-9343-131449E0AAF4Q26851894-2A049A3E-5019-4155-8F8B-532896167D12Q28304978-D2EB2BF4-C3B4-446E-8D83-0ACA1421AA5EQ33398180-962B0A76-4ED5-4BC3-BAB9-58170947CC98Q33402848-2834F04E-1B0F-4236-B3F4-D5FD3F5A4E5DQ33405241-4C5442AC-F86F-49E4-B991-DF0D0B9910DFQ33416851-D47D51AD-4879-4DA5-9484-408B84657A05Q33420037-C2BFBA3D-EFFC-4E76-A8B3-D9A8D5BCE385Q33432285-24F76E52-CAAF-472D-B5FD-C11079376556Q33435810-2EFC3581-1B96-48AE-839B-C4CDE2EEE32AQ34166859-722C908A-2A3A-4AAD-8C21-DA0E7AE2E563Q34302770-BC6EFC3D-EC16-4CFB-987A-D2681044B485Q34344384-1A78309E-4222-4C72-870E-BDF14D3A8121Q34360366-7C25C42A-924F-45D0-8743-964E12DA40B7Q34549335-FE969B4B-EEF6-46E5-89DC-475638B2FD23Q34718163-06433396-629E-49A3-B053-D6F09886D582Q35132271-D3DB7042-A318-4F95-A6C6-F2F840675740Q35572748-6704A99C-24D1-4F6F-9AB1-1DE34C533829Q35743852-4597D4DC-4784-4FD5-A383-6FF05EBBA17EQ36311347-ED06D741-E6CB-4352-92BC-759FA3F5B6DFQ36318162-C4008501-1F60-44D3-9FF4-9E8E064AEE65Q36765086-0570162D-3D02-4B4E-8CB3-E5A2BCAE1B2AQ36938773-E8E2A3D0-97B6-4D86-A164-0249749D72F5Q37034988-7EB93F23-5412-4C0F-96BF-3C9D53360904Q37163590-2ABB04FC-A5BB-41FD-96B3-7A27A2AC1326Q37275858-9E6AEB71-78EA-4C91-8023-DD5940F0B404Q37310619-BC649D88-10D4-4616-A5C8-CE42D10A5F41Q37704367-6E450E63-BF23-4770-B5E5-74B473C0EBFAQ37815421-E31B3762-A10B-46ED-9462-2F582AB66D72Q37832939-B5452DEB-6467-4A5C-84F3-F96351262B59Q37860336-8FA4E634-C584-444E-B703-36E6B5B4272CQ37891692-505D8EE6-3EFF-471B-9C7B-CAB9F4FEB997Q37955231-EB1B866A-E870-4667-A0BD-087F70F6E919Q37983791-AFFB8F3C-F201-426A-86E9-F80A3378FE7FQ38014534-47E127DB-9E25-4A57-800C-1716E69D62B3Q38111770-D8E5F14F-2903-473D-9C45-4EC1E47FF931Q38130749-7F3F83BA-1105-4199-A6B8-2C6783E1157CQ38159973-1BD5009D-D1E7-40A3-9006-28ECBA1BA59BQ38187684-6F8D8174-2A23-499A-851D-090E616DD2A5Q38292400-4B8EB941-D96A-4830-B49B-193521BDF772
P2860
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
@en
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
@nl
type
label
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
@en
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
@nl
prefLabel
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
@en
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
@nl
P356
P1433
P1476
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms
@en
P2093
P2888
P304
P356
10.1038/LEU.2008.280
P577
2008-10-09T00:00:00Z